RecruitingNot ApplicableNCT04612907

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

A Randomized Phase III, Multicenter Study to Evaluate Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

Sponsor

Umeå University

Enrollment

420 participants

Start Date

Oct 31, 2022

Study Type

INTERVENTIONAL

Conditions

Radiotherapy Side Effect Prostate Cancer Metastatic Cancer

Summary

de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.

Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria4

Signed Informed Consent
Histological confirmed prostate cancer
Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes
baseline E-PROM

Exclusion Criteria5

High burden metastatic prostate cancer including all with visceral mets.
Unable to comply with study procedures.
Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy
Radiation treatment start later than nine months after the prostate cancer diagnosis.
Severe micturition problems, IPSS \> 20 ( International Prostate Symptom Score)